{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:11:41Z","timestamp":1792131101838,"version":"4.4.0"},"reference-count":100,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several hematological malignancies. Its use has continued to grow, with an estimated 23,500 transplants performed annually in the United States alone. The acute toxicities that occur from conditioning chemotherapy can impact the peri-transplant period and have substantial implications on patients\u2019 tolerability and outcomes, irrespective of the treatment of their disease. Chemotherapy-induced nausea vomiting (CINV), mucositis, transplant-associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome, also known as a veno-occlusive disease (SOS\/VOD) can all have significant implications for patients. These acute complications begin with the start of conditioning chemotherapy and add to potential toxicity for patients throughout the early post-transplant period, from Day +30 for CINV, mucositis, and SOS, and which can continue through at least Day +100 with the onset of TA-TMA. These toxicities must be prevented and managed appropriately. This review will summarize the literature surrounding them and guide their management.<\/jats:p>","DOI":"10.46989\/001c.94952","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T09:02:01Z","timestamp":1712134921000},"source":"Crossref","is-referenced-by-count":16,"title":["Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation"],"prefix":"10.46989","volume":"6","author":[{"given":"Jana","family":"Sawyer","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01c9rqr26","id-type":"ROR","asserted-by":"publisher"}],"name":"VA Tennessee Valley Healthcare System","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Elliott","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01c9rqr26","id-type":"ROR","asserted-by":"publisher"}],"name":"VA Tennessee Valley Healthcare System","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Orton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Sowell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gatwood","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Shultes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01c9rqr26","id-type":"ROR","asserted-by":"publisher"}],"name":"VA Tennessee Valley Healthcare System","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","article-title":"Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloablative stem cell transplantation","volume":"25","author":"Lindsey E. Roeker","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"7","key":"ref2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"R.J. Gralla","year":"2014","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"16","key":"ref3","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2217\/fon-2020-0834","article-title":"Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study","volume":"17","author":"Sandip Mukhopadhyay","year":"2021","journal-title":"Future Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1479-6694","issn-type":"print"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.31557\/apjcp.2022.23.6.2137","article-title":"Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist","volume":"23","author":"Sitthi Sukauichai","year":"2022","journal-title":"Asian Pacific Journal of Cancer Prevention","ISSN":"https:\/\/id.crossref.org\/issn\/2476-762X","issn-type":"print"},{"issue":"7","key":"ref5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bcp.13242","article-title":"Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis","volume":"83","author":"Ting Yang","year":"2017","journal-title":"British Journal of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0306-5251","issn-type":"print"},{"issue":"705866","key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.705866","article-title":"The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis","volume":"11","author":"Dong-Yang Wang","year":"2021","journal-title":"Frontiers in Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/2234-943X","issn-type":"print"},{"key":"ref7","article-title":"Understanding Nausea and Vomiting","author":"American Cancer Society","year":"2020"},{"key":"ref8","first-page":"S259","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","author":"N. Adel","year":"2017","journal-title":"Am J Manag Care"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.10232","article-title":"Mucositis in patients with hematologic malignancies: an overview","volume":"92","author":"P. Niscola","year":"2007","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc1318","article-title":"The pathobiology of mucositis","volume":"4","author":"Stephen T. Sonis","year":"2004","journal-title":"Nature Reviews Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1474-175X","issn-type":"print"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/1097-0142(19930901)72:5<1612::aid-cncr2820720520>3.0.co;2-q","article-title":"A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients","volume":"72","author":"S. Woo","year":"1993","journal-title":"Cancer"},{"issue":"7","key":"ref12","doi-asserted-by":"publisher","first-page":"409.e1","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes","volume":"28","author":"Rachel Phelan","year":"2022","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"5","key":"ref13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","article-title":"Mucositis after hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotexate-containing graft-versus-host disease prophylaxis regimens","volume":"11","author":"Corey Cutler","year":"2005","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"8","key":"ref14","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/jco.2001.19.8.2201","article-title":"Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation","volume":"19","author":"Stephen T. Sonis","year":"2001","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"5","key":"ref15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis","volume":"109","author":"Dorothy M. Keefe","year":"2007","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00520-004-0726-y","article-title":"Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients","volume":"13","author":"Yoshinobu Aisa","year":"2005","journal-title":"Supportive Care in Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0941-4355","issn-type":"print"},{"issue":"4","key":"ref17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/10428190400029957","article-title":"Prevention of high-dose melphalan-induced mucositis by cryotherapy","volume":"46","author":"Alfredo Tartarone","year":"2005","journal-title":"Leukemia &amp; Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa04012","article-title":"Palifermin for oral mucositis after intensive therapy for hematologic cancers","volume":"351","author":"R. Spielberger","year":"2004","journal-title":"NEJM"},{"issue":"19","key":"ref19","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Sharon Elad","year":"2020","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"10","key":"ref20","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1007\/s00520-019-04890-2","article-title":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","volume":"27","author":"Yehuda Zadik","year":"2019","journal-title":"Supportive Care in Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0941-4355","issn-type":"print"},{"issue":"5","key":"ref21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/0148607109341804","article-title":"A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation","volume":"33","author":"David Allen August","year":"2009","journal-title":"Journal of Parenteral and Enteral Nutrition","ISSN":"https:\/\/id.crossref.org\/issn\/0148-6071","issn-type":"print"},{"issue":"9","key":"ref22","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s12325-022-02184-4","article-title":"The role of complement in HSCT-TA: Basic science to clinical practice","volume":"39","author":"Seppo Meri","year":"2022","journal-title":"Advances in Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/0741-238X","issn-type":"print"},{"issue":"100278","key":"ref23","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends","volume":"26","author":"Kush Gupta","year":"2021","journal-title":"Cancer Treatment and Research Communications","ISSN":"https:\/\/id.crossref.org\/issn\/2468-2942","issn-type":"print"},{"issue":"8","key":"ref24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Joanna A. Young","year":"2021","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"2","key":"ref25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"James N. George","year":"2004","journal-title":"Transfusion","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1132","issn-type":"print"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"M.L. Schoettler","year":"2023","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"4","key":"ref27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Sonata Jodele","year":"2014","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"6","key":"ref28","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy","volume":"189","author":"Narendranath Epperla","year":"2020","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Christopher E. Dandoy","year":"2020","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"11","key":"ref30","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Michelle Schoettler","year":"2020","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","article-title":"Thrombotic Microangiopathy in Haematopoietic stem cell transplantation: Diagnosis and treatment","volume":"69","author":"Cecilia M. Choi","year":"2009","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"2","key":"ref32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","author":"Sonata Jodele","year":"2016","journal-title":"Transfusion and Apheresis Science","ISSN":"https:\/\/id.crossref.org\/issn\/1473-0502","issn-type":"print"},{"key":"ref33","series-title":"Prescribing information","article-title":"Drug Approvals and Databases. CABLIVI\u00ae (caplacizumab-yhdp) injection, for intravenous or subcutaneous use. Prescribing information: 2020","author":"U.S. Food & Drug Administration","year":"2020"},{"key":"ref34","article-title":"Nausea and Vomiting Related to Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version","author":"National Cancer Institute.","year":"2023"},{"issue":"8","key":"ref35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation","volume":"11","author":"Vincent T. Ho","year":"2005","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"6","key":"ref36","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation\u2013associated thrombotic microangiopathy","volume":"118","author":"Benjamin L. Laskin","year":"2011","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"5","key":"ref37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Wing-Yan Au","year":"2007","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.1111\/j.1399-3046.2010.01408.x","article-title":"Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation","volume":"16","author":"Sonata Jodele","year":"2012","journal-title":"Pediatric Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1397-3142","issn-type":"print"},{"issue":"2","key":"ref39","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/ijms24021159","article-title":"Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand","volume":"24","author":"Ioanna Lazana","year":"2023","journal-title":"International Journal of Molecular Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/1422-0067","issn-type":"print"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbmt.2006.11.020","article-title":"Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment","volume":"13","author":"Betul Oran","year":"2007","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"3","key":"ref41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal","volume":"25","author":"Ang Li","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"13","key":"ref42","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/bloodadvances.2020002007","article-title":"Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT","volume":"4","author":"Hiroyuki Matsui","year":"2020","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"key":"ref43","article-title":"Drug Approvals and Databases. DEFITELIO\u00ae (defibrotide sodium) injection, for intravenous use. Prescribing Information","author":"U.S. Food & Drug Administration","year":"2022","journal-title":"Prescribing Information. Issued"},{"issue":"6","key":"ref44","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"P Corti","year":"2002","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"key":"ref45","article-title":"Antiemesis. Version 2.2023.","author":"NCCN Guidelines","year":"2023"},{"issue":"1","key":"ref46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41409-018-0256-8","article-title":"Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy","volume":"54","author":"M. E. Mart\u00ednez-Mu\u00f1oz","year":"2018","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"5","key":"ref47","doi-asserted-by":"publisher","first-page":"e29641","DOI":"10.1002\/pbc.29641","article-title":"A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients","volume":"69","author":"Christine S. Higham","year":"2022","journal-title":"Pediatric Blood &amp; Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1545-5009","issn-type":"print"},{"issue":"5","key":"ref48","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation","volume":"52","author":"L Yeates","year":"2017","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"key":"ref49","article-title":"SOLIRIS\u00ae (eculizumab) injection, for intravenous use. Prescribing Information","year":"2020"},{"key":"ref50","article-title":"National Institute of Health","author":"ClinicalTrials.gov","journal-title":"US Department of Health and Human Services"},{"issue":"4","key":"ref51","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation\u2013Associated Thrombotic Microangiopathy","volume":"20","author":"Sonata Jodele","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"9","key":"ref52","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"S Vasu","year":"2016","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"9","key":"ref53","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/tp.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC","volume":"99","author":"Flore Sicre de Fontbrune","year":"2015","journal-title":"Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1337","issn-type":"print"},{"issue":"2","key":"ref54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/107602961559943","article-title":"Eculizumab in Transplant-Associated Thrombotic Microangiopathy","volume":"23","author":"P. Dhakal","year":"2017","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"3","key":"ref55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Sonata Jodele","year":"2020","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"6","key":"ref56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Ikuo Sekine","year":"2013","journal-title":"Cancer Science","ISSN":"https:\/\/id.crossref.org\/issn\/1347-9032","issn-type":"print"},{"issue":"4","key":"ref57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Cathy Q. Fan","year":"2014","journal-title":"Journal of Clinical and Experimental Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0973-6883","issn-type":"print"},{"issue":"6","key":"ref58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"M Mohty","year":"2015","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"3","key":"ref59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment","volume":"22","author":"Jean-Hugues Dalle","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"2","key":"ref60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Jason A. Coppell","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"11","key":"ref61","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Enric Carreras","year":"2011","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"3","key":"ref62","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment","volume":"22","author":"Jean-Hugues Dalle","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"1","key":"ref63","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"George B. McDonald","year":"1984","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"issue":"7","key":"ref64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"25","author":"Selim Corbacioglu","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"6","key":"ref65","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease","volume":"29","author":"Laurie D. DeLeve","year":"1999","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"issue":"10","key":"ref66","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/imj.13550","article-title":"New insights into sinusoidal obstruction syndrome","volume":"47","author":"Andrea Piccin","year":"2017","journal-title":"Internal Medicine Journal","ISSN":"https:\/\/id.crossref.org\/issn\/1444-0903","issn-type":"print"},{"issue":"6","key":"ref67","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin\u2013cyclophosphamide-based chemotherapy","volume":"19","author":"David G. Warr","year":"2011","journal-title":"Supportive Care in Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0941-4355","issn-type":"print"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.3816\/clm.2002.s.007","article-title":"anagement of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg)","volume":"2","author":"George B. McDonald","year":"2002","journal-title":"Clinical Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1526-9655","issn-type":"print"},{"issue":"5","key":"ref69","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Martha Wadleigh","year":"2003","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"5","key":"ref70","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","article-title":"Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis","volume":"26","author":"Vincent T. Ho","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"1","key":"ref71","doi-asserted-by":"publisher","first-page":"2018001","DOI":"10.4084\/mjhid.2018.001","article-title":"Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide.","volume":"10","author":"Alessia Castellino","year":"2018","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases","ISSN":"https:\/\/id.crossref.org\/issn\/2035-3006","issn-type":"print"},{"issue":"4","key":"ref72","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/hep.23533","article-title":"Hepatobiliary complications of hematopoietic cell transplantation, 40 years on","volume":"51","author":"George B. McDonald","year":"2010","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"issue":"10","key":"ref73","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.bbmt.2020.06.016","article-title":"Imaging in Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"26","author":"Sherwin S. Chan","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"7","key":"ref74","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Mohamad Mohty","year":"2023","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"4","key":"ref75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"George B. McDonald","year":"1993","journal-title":"Annals of Internal Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"6","key":"ref76","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"RICHARD J. Jones","year":"1987","journal-title":"Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1337","issn-type":"print"},{"issue":"2","key":"ref77","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"S Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"key":"ref78","article-title":"Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting","volume":"2","author":"Sayantani Ghosh","year":"2010","journal-title":"International Journal of Collaborative Research on Internal Medicine & Public Health"},{"issue":"6","key":"ref79","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Mitchell S. Cairo","year":"2020","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"12Pt1","key":"ref80","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"James H. Essell","year":"1998","journal-title":"Annals of Internal Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"1","key":"ref81","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"K. Ohashi","year":"2000","journal-title":"Am J Hematol"},{"issue":"1","key":"ref82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","article-title":"Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study","volume":"20","author":"Tapani Ruutu","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"2","key":"ref83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Jason Tay","year":"2007","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"1","key":"ref84","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/oli.2006.16.105","article-title":"Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action","volume":"16","author":"Noah Kornblum","year":"2006","journal-title":"Oligonucleotides","ISSN":"https:\/\/id.crossref.org\/issn\/1545-4576","issn-type":"print"},{"issue":"4","key":"ref85","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1399-0012.2012.01604.x","article-title":"Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review","volume":"26","author":"Lifei Zhang","year":"2012","journal-title":"Clinical Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0902-0063","issn-type":"print"},{"issue":"9823","key":"ref86","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Selim Corbacioglu","year":"2012","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"5","key":"ref87","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/s2352-3026(23)00011-x","article-title":"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial","volume":"10","author":"Stephan A Grupp","year":"2023","journal-title":"The Lancet Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/2352-3026","issn-type":"print"},{"issue":"22","key":"ref88","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood.v114.22.654.654","article-title":"Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.","volume":"114","author":"Paul G. Richardson","year":"2009","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"2","key":"ref89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <i>CYP2D6<\/i> genotype and use of ondansetron and tropisetron","volume":"102","author":"GC Bell","year":"2017","journal-title":"Clinical Pharmacology &amp; Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"issue":"13","key":"ref90","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Paul G. Richardson","year":"2016","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref91","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population - PubMed","author":"Paul G., et al. Richardson","year":"1998","journal-title":"Blood"},{"issue":"4","key":"ref92","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study","volume":"111","author":"R. Chopra","year":"2000","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"13","key":"ref93","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"P. G. Richardson","year":"2002","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"2","key":"ref94","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"S Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"7","key":"ref95","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/pbc.20934","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children","volume":"48","author":"Sean R. Bulley","year":"2007","journal-title":"Pediatric Blood &amp; Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1545-5009","issn-type":"print"},{"issue":"7","key":"ref96","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.00","article-title":"Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial","volume":"16","author":"P.G. Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"ref97","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/2040620712441943","article-title":"Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease","volume":"3","author":"Paul G. Richardson","year":"2012","journal-title":"Therapeutic Advances in Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/2040-6207","issn-type":"print"},{"issue":"1","key":"ref98","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Paul G. Richardson","year":"2017","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"3","key":"ref99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2019.10.024","article-title":"Incidence, predictors, and outcomes of veno-occlusive disease\/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation","volume":"26","author":"Clinton Lewis","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"7","key":"ref100","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"M. Aapro","year":"2014","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/94952-prevention-and-management-of-acute-toxicities-from-conditioning-regimens-during-hematopoietic-stem-cell-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:50:53Z","timestamp":1791726653000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/94952-prevention-and-management-of-acute-toxicities-from-conditioning-regimens-during-hematopoietic-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.94952","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]}}}